Apelin-13通过激活ERK1/2通路复苏布比卡因诱导的心脏停搏

doi:10.3969/j.issn.2095-9400.2020.06.003

Abstract
Figure/Table
References (0)
Related Citation (13)

Download: PDF (1508 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the role and mechanism of Apelin-13 in bupivacaine-induced cardiac arrest in rats. Methods: Thirty-five male SD rats were randomly divided into three groups: sham operation group (Sham group, n=5), bupivacaine+saline group (A group, n=15), bupivacaine+Apelin (B group, n=15). Rat femoral artery and vein open, intravenous bolus of bupivacaine 30 mg·kg-1 was injected to cause cardiac arrest. B group was immediately given 150 μg of Apelin-13, and A group was injected intravenously with the same amount of normal saline. Cardiac arrest was recorded as zero and cardiopulmonary resuscitation (CPR) was started until ROSC (return of spontaneous circulation) or the end of a 40 min period. The survivors were sacrificed 120 minutes after ROSC observation, and myocardial tissue was retained. The rate of the recovery, the rate of survival, the time from initiation of bupivacaine to cardiac arrest (T0), the time from the start of CPR to the first spontaneous heartbeat (Ts), and the time from the start of CPR to ROSC (Tr) and hemodynamics were recorded. The expression of APJ, ERK1/2 and p-ERK1/2 protein in myocardial tissue was detected by Western blot and the concentration of Apelin-13 in myocardial tissue by ELISA. Results: The results showed that compared with the Sham group, the expression of Apelin-13, APJ, p-ERK1/2 protein were signally down-regulated (P<0.05) in the A group. Compared with the A group, the recovery rate and the survival rate were increased, Tr shortened, he modynamics improved significantly after ROSC and the expressions of Apelin-13, APJ, p-ERK1/2 protein were signally up-regulated (P<0.05) in the B group. Conclusion: Apelin-13 can rescue bupivacaine-induced cardiac arrest in rats, and the mechanism may be related to activation of ERK1/2 pathway protein phosphorylation.

Key words： Apelin-13 bupivacaine cardiac arrest ERK1/2

Received: 23 November 2019

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Shi
	HE Yuting
	CHEN Zhengjie
	LIN Tingting
	WANG Quanguang
	LIN Li’na

URL:

https://xb.wmu.edu.cn/EN/ 10.3969/j.issn.2095-9400.2020.06.003 OR https://xb.wmu.edu.cn/EN/Y2020/V50/I6/444

[1] NELSON M, REENS A, REDA L, et al. Profound prolonged bradycardia and hypotension after interscalene brachial plexus block with bupivacaine[J]. J Emerg Med, 2018, 54(3): e41-e43.
[2] CHAPMAN N A, DUPRE D J, RAINEY J K. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR[J]. Biochem Cell Biol, 2014, 92(6): 431-440.
[3] GALANTH C, HUS-CITHAREL A, LI B, et al. Apelin in the control of body fluid homeostasis and cardiovascular functions[J]. Curr Pharm Des, 2012, 18(6): 789-798.
[4] YU X H, TANG Z B, LIU L J, et al. Apelin and its receptor APJ in cardiovascular diseases[J]. Clin Chim Acta, 2014, 428: 1-8.
[5] YEGANEH-HAJAHMADI M, NAJAFIPOUR H, ROSTAMZADEH F. The differential effects of low and high doses of apelin through opioid receptors on the blood pressure of rats with renovascular hypertension[J]. Hypertens Res, 2017, 40(8): 732-737.
[6] 刘乐, 金周晟, 南芙蓓, 等. 两种脂肪乳剂输注方案治疗布比卡因诱导的大鼠心脏停搏的效果比较[J]. 温州医科大学学报, 2017, 47(7): 514-518.
[7] LI Z, XIA Y, DONG X, et al. Lipid resuscitation of bupivacaine toxicity: long-chain triglyceride emulsion provides benefits over long- and medium-chain triglyceride emulsion [J]. Anesthesiology, 2011, 115(6): 1219-1228.
[8] ABDELMALEK D, SCHWARZ E S, SAMPSON C, et al. Life-threatening diphenhydramine toxicity presenting with seizures and a wide complex tachycardia improved with intravenous fat emulsion[J]. Am J Ther, 2014, 21(6): 542-544.
[9] YEGANEH-HAJAHMADI M, NAJAFIPOUR H, FARZANEH F, et al. Effect of apelin on cardiac contractility in acute reno-vascular hypertension: the role of apelin receptor and kappa opioid receptor heterodimerization[J]. Iran J Basic Med Sci, 2018, 21(12): 1305-1315.
[10] YAMALEYEVA L M, SHALTOUT H A, VARAGIC J. Apelin-13 in blood pressure regulation and cardiovascular disease[J]. Curr Opin Nephrol Hypertens, 2016, 25(5): 396-403.
[11] CHENG J, LUO X, HUANG Z, et al. Apelin/APJ system: a potential therapeutic target for endothelial dysfunction-related diseases[J]. J Cell Physiol, 2019, 234(8): 12149-12160.
[12] SZOKODI I, KERKELA R, KUBIN A M, et al. Functionally opposing roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the regulation of cardiac contractility[J]. Circulation, 2008, 118(16): 1651-1658.
[13] YIN L, ZHANG P, LI C, et al. Apelin13 promotes cell proliferation in the H9c2 cardiomyoblast cell line by triggering extracellular signalregulated kinase 1/2 and protein kinase B phosphorylation[J]. Mol Med Rep, 2018, 17(1): 447-451.
[14] ROSTAMZADEH F, NAJAFIPOUR H, YEGANEH-HAJAHMADI M, et al. Heterodimerization of apelin and opioid receptors and cardiac inotropic and lusitropic effects of apelin in 2K1C hypertension: role of pERK1/2 and PKC [J]. Life Sci, 2017, 191: 24-33.
[15] PERJES A, SKOUMAL R, TENHUNEN O, et al. Apelin increases cardiac contractility via protein kinase cepsilon- and extracellular signal-regulated kinase-dependent mechanisms [J]. PLoS One, 2014, 9(4): e93473.